The utilisation of statistical analysis plan (SAP) has the potential to enhance the reliability, transparency, and impartiality of statistical analysis procedures in the context of clinical studies. These plans are primarily designed for late phase clinical studies, namely phase Ⅱ and phase Ⅲ randomised controlled trials. The extended SAP reporting guidelines for early phase clinical studies, i.e., phase Ⅰ clinical studies and phase Ⅱ non-randomised controlled trials, have been expanded from the original reporting guidelines in six key areas: trial purpose, design, Bayesian statistics, data simulation, sample size, and the application of ICH E9 (R1). The expanded reporting guidelines facilitate the standardisation of SAP for early phase clinical trials, enhance the transparency and reproducibility of early phase clinical studies, and thereby improve the quality of early phase clinical studies. This, in turn, plays a pivotal role in later phase clinical studies.
Citation： LI Yufei, LIU Jianping, ZHANG Wenqian, ZHANG Ying. Interpretation of the statistical analysis plan (SAP) extended reporting guidelines and their enlightenment for the design of early stage clinical studies of new drugs. Chinese Journal of Evidence-Based Medicine, 2024, 24(11): 1347-1351. doi: 10.7507/1672-2531.202405191 Copy